Replies to post #2121 on Akers Biosciences Inc. (AKER)

[leifsmith]

Dr. Patrizio P. Caturegli, Johns Hopkins University School of Medicine takes Jonnie Williams' discovery seriously.

Dr. Patrizio P. Caturegli is an associate professor of pathology at the Johns Hopkins University School of Medicine. An immunopathologist, Dr. Caturegli is the director of the Johns Hopkins Hypophysitis Center and serves on the faculty of the Autoimmune Disease Research Center.

His clinical and research focus is autoimmune diseases of the endocrine glands. These include myocarditis, thyroiditis, hypophysitis, Sjogren''s syndrome, and complete congenital heart blockage.

Dr. Caturegli earned his medical degree from Italy’s Faculty of Medicine E Chirurgua University of Pisa. He completed a residency in endocrinology at the University of Pisa and a residency in pathology at Johns Hopkins. He performed a fellowship in public health at Johns Hopkins where he also earned a M.P.H. from Hopkins’ Bloomberg School of Public Health. He joined the Johns Hopkins faculty in 1999.

He is American Board of Pathology-certified in clinical pathology and has published more than 100 journal articles.

https://www.hopkinsmedicine.org/profiles/results/directory/profile/0009037/patrizio-caturegli

Caturegli on Anatabine

Caturegli P, De Remigis A, Ferlito M, Landek-Salgado MA, Iwama S, Tzou SC, Ladenson PW. Anatabine ameliorates experimental autoimmune thyroiditis. Endocrinology. 2012 Sep;153(9):4580-7

Caturegli P, De Remigis A, Ferlito M, Landek-Salgado MA, Iwama S, Tzou SC, Ladenson PW. Anatabine ameliorates experimental autoimmune thyroiditis. Endocrinology. 2012 Sep;153(9):4580-7 — https://pubmed.ncbi.nlm.nih.gov/22807490/

knuts4oe: Thank you for your contributions to this and other boards discussing anatabine, Anatabloc, and its possible successor alkaloid molecules, such as MYMD-1, which we hope will become Akers principle reason for being.